A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension
Information source: Alcon Research
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Open-Angle Glaucoma; Ocular Hypertension
Intervention: Brimonidine Tartrate Ophthalmic Solution (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Alcon Research
Summary
The primary objective of this study is to compare the safety and efficacy of Brimonidine
Tartrate Ophthalmic Solution, 0. 15% in patients with open-angle glaucoma or ocular
hypertension.
Clinical Details
Official title: A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Eligibility
Minimum age: 2 Months.
Maximum age: N/A.
Gender(s): Both.
Criteria:
- Patients of any race
- two (2) years of age or older
- of either sex
- diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment
dispersion component)or ocular hypertension
Locations and Contacts
Alcon Call Center, Fort Worth, Texas, United States
Additional Information
Starting date: January 2003
Last updated: August 4, 2008
|
